Daniel Grasso, APRN
Psychiatric/Mental Health · Flushing, MINPI 1649900234
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 53.7% of the total. 2025 is the largest year on record at $8,751, more than ten times the $134 reported in 2022. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $34.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$7K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$773
- Teva Pharmaceuticals USA, Inc.$611
- Axsome Therapeutics, Inc.$610
- Corium, LLC$590
- Supernus Pharmaceuticals, Inc.$464
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$5,21243%
- Travel & lodging$2132%
- Food & beverage$6,47053%
- Education$2622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 67 | $6,522 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $773 |
| Teva Pharmaceuticals USA, Inc. | 28 | $611 |
| Axsome Therapeutics, Inc. | 25 | $610 |
| Corium, LLC | 30 | $590 |
| Supernus Pharmaceuticals, Inc. | 32 | $464 |
| Alkermes, Inc. | 20 | $458 |
| Lundbeck LLC | 17 | $347 |
| Neurocrine Biosciences, Inc. | 18 | $328 |
| E.r. Squibb & Sons, L.L.C. | 19 | $285 |
| AbbVie | 16 | $240 |
| Vanda Pharmaceuticals Inc. | 13 | $239 |
| Collegium Pharmaceutical, Inc. | 3 | $155 |
| Tempus AI, Inc | 7 | $149 |
| Johnson & Johnson | 5 | $131 |
| Noven Therapeutics, LLC | 4 | $83 |
| Validus Pharmaceuticals LLC | 2 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,157 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 68 | $307,384 |
| RexultiBrexpiprazole | 277 | $220,811 |
| AustedoDeutetrabenazine | 25 | $101,619 |
| NuplazidPimavanserin Tartrate | 30 | $73,948 |
| CaplytaLumateperone Tosylate | 42 | $44,915 |
| AuvelityDextromethorphan Hbr/Bupropion | 54 | $36,573 |
| TrintellixVortioxetine Hydrobromide | 89 | $20,928 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $17,444 |
| FanaptIloperidone | 14 | $16,291 |
| EmsamSelegiline | 20 | $15,190 |
| SecuadoAsenapine | 15 | $11,638 |
| VraylarCariprazine Hcl | 14 | $10,129 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 23 | $4,587 |
| Divalproex Sodium | 49 | $3,403 |
| Paliperidone ErPaliperidone | 27 | $2,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $611 | $409,00493 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $6,522 | $220,811277 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $773 | $44,91542 claims |
| Axsome Therapeutics, Inc.Auvelity | $610 | $36,57354 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $20,92889 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $239 | $16,29114 claims |
| AbbVieVraylar | $240 | $10,12914 claims |
| Lilly USA, LLCOlanzapine | $18 | $83045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Flushing
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.